Selective RET Inhibitor Dosing for Lower-Toxicity Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for RET-altered cancers, such as non-small cell lung cancer and thyroid cancer, lack selective RET inhibitors with appropriate dosing and safety profiles, leading to significant toxicity and limited response durations, and there are no effective therapies for patients with disease progression or intolerance to multikinase inhibitors.
Innovation Solution
Development of a selective RET inhibitor, Compound 1, administered at specific dosages (60-400 mg once daily) to target RET alterations, achieving sustained down-regulation of effect markers and reducing tumor growth in RET-altered cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multikinase inhibitors are used to treat RET-altered cancers, then some tumor growth inhibition is achieved, but significant toxicity and limited response durations occur
Solution Approach 1:
The patent extracts and isolates the specific RET kinase target from the broader multikinase inhibitor approach. Compound 1 is designed to selectively inhibit RET kinase while sparing other kinases, thereby maintaining anti-tumor efficacy against RET-altered cancers while reducing off-target toxicities associated with multikinase inhibition
Solution Approach 2:
The invention applies local quality by creating a inhibitor with selective action specifically at the RET kinase site. Compound 1 exhibits preferential binding and inhibition of RET kinase over other kinases, concentrating the therapeutic effect locally at the disease driver while minimizing systemic toxicity to other pathways
2Productivity
If multikinase inhibitors are administered to RET-altered cancer patients, then some clinical response is achieved, but response duration is limited and disease progression occurs
Solution Approach 1:
The patent segments the anti-tumor activity from the toxic effects by creating a selective RET inhibitor. This segmentation allows sustained targeted inhibition of the RET pathway driving tumor growth and progression, leading to longer response durations compared to the transient effects seen with multikinase inhibitors
Solution Approach 2:
Compound 1 acts as a selective intermediary that specifically blocks RET kinase signaling without broadly inhibiting other kinases. This mediated inhibition provides sustained clinical response by continuously blocking the oncogenic RET pathway while avoiding the tolerance and resistance issues that limit response duration with multikinase inhibitors
3Reliability
If selective RET inhibitor Compound 1 is administered at higher dosages, then tumor reduction efficacy is improved, but safety and tolerability may be compromised
Solution Approach 1:
The patent optimizes the dosage parameters of Compound 1 to achieve maximum tumor reduction efficacy while maintaining an acceptable safety profile. By carefully controlling the concentration and exposure levels of the selective RET inhibitor, the invention achieves effective RET pathway suppression without exceeding the tolerability threshold, unlike multikinase inhibitors that require dose reductions due to toxicity
Data Source
AI summary
Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.